Table 1.

Clinical characteristics of patients receiving ACT as well as their cell dose, dominant Vβ-gene usage and short-term outcomes

Patient	Subtype	Age	Prior treatment	Sites of active disease at time of study treatment	Cell dose (×109)	Dominant clone Vβ-gene	Clinical outcome
Cy1	MRCL	35	A/I, Rtx	Lung	27.5	TRBV5-4*01	Stable disease, resected to NED. Progression 1 year after ECT
Cy2	SS	26	A/I	Lung, liver	20	TRBV12-3*01	Progression at 8–10 weeks despite initial 20% reduction in a liver lesion at 4 weeks
Cy3	SS	27	Sorafenib, epirubicin, ifosfamide, Rtx	Lung	19.8	TRBV4*-1*01	Progression at 8–10 weeks, despite regression at 4 weeks post-ECT with 36% reduction in a lung lesion
Cy4	MRCL	62	A/I, dacarbazine, gem/tax, sorafenib, capecitabine, erlotinib, pazopanib	Lung, mediastinum, abdomen/retroperitoneum (multiple sites), pelvis, bone	19	TRBV9*01	Progression at 8–10 weeks, despite regression in some lesions including 16% reduction in a mediastinal lesion with improved pain

Prior lines of treatment and sites of disease are at the time of trial enrollment.

ACT, adoptive cellular therapy; ECT, electroconvulsive therapy; MRCL, myxoid/round cell liposarcoma; NED, no evidence of disease; PBMC, peripheral blood mononuclear cells; SS, synovial sarcoma.